-
Je něco špatně v tomto záznamu ?
Drug survival analysis of etanercept compared with monoclonal antibody tumour necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a propensity score-matched analysis from the Czech ATTRA registry
Š. Tichý, L. Nekvindová, J. Baranová, J. Vencovský, K. Pavelka, P. Horák, J. Závada
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, srovnávací studie
- MeSH
- adalimumab terapeutické užití MeSH
- ankylózující spondylitida * farmakoterapie mortalita MeSH
- antirevmatika * terapeutické užití MeSH
- dospělí MeSH
- etanercept * terapeutické užití MeSH
- infliximab terapeutické užití MeSH
- Kaplanův-Meierův odhad MeSH
- lidé středního věku MeSH
- lidé MeSH
- monoklonální protilátky terapeutické užití MeSH
- psoriatická artritida * farmakoterapie mortalita MeSH
- registrace * MeSH
- revmatoidní artritida * farmakoterapie mortalita MeSH
- senioři MeSH
- tendenční skóre * MeSH
- TNF-alfa * antagonisté a inhibitory MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
- Geografické názvy
- Česká republika MeSH
OBJECTIVES: To compare the drug survival of etanercept to monoclonal tumour necrosis factor-α inhibitors in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. METHODS: Patients initiating first line biological therapy with tumour necrosis factor-α were propensity score matched and compared for drug survival with a Kaplan-Meier analysis. RESULTS: We matched 657 to 657 patients in rheumatoid arthritis, the median survival time on etanercept was 44.6 months vs. 36.8 months on monoclonal antibody tumour necrosis factor-α inhibitors, with a hazard ratio of 0.94, p = 0.416 We matched 187 to 356 patients in ankylosing spondylitis, the median survival time on etanercept was 75.1 compared to 68.0 months, hazard ratio of 0.78, p = 0.087 We matched 81 to 160 psoriatic arthritis patients, the median survival time on etanercept was 35.8. compared to 65.7 months, hazard ratio 1.61, p = 0.011. Patients treated with etanercept had significantly worse psoriasis scoring during follow up. CONCLUSIONS: We found comparable survival in rheumatoid arthritis and ankylosing spondylitis. In psoriatic arthritis, we found significantly shorter survival on etanercept, possibly due to worse response of skin and nail manifestations.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009772
- 003
- CZ-PrNML
- 005
- 20250429135057.0
- 007
- ta
- 008
- 250415s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/03009742.2024.2381746 $2 doi
- 035 __
- $a (PubMed)39105330
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Tichý, Š $u Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0009000604065663
- 245 10
- $a Drug survival analysis of etanercept compared with monoclonal antibody tumour necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a propensity score-matched analysis from the Czech ATTRA registry / $c Š. Tichý, L. Nekvindová, J. Baranová, J. Vencovský, K. Pavelka, P. Horák, J. Závada
- 520 9_
- $a OBJECTIVES: To compare the drug survival of etanercept to monoclonal tumour necrosis factor-α inhibitors in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. METHODS: Patients initiating first line biological therapy with tumour necrosis factor-α were propensity score matched and compared for drug survival with a Kaplan-Meier analysis. RESULTS: We matched 657 to 657 patients in rheumatoid arthritis, the median survival time on etanercept was 44.6 months vs. 36.8 months on monoclonal antibody tumour necrosis factor-α inhibitors, with a hazard ratio of 0.94, p = 0.416 We matched 187 to 356 patients in ankylosing spondylitis, the median survival time on etanercept was 75.1 compared to 68.0 months, hazard ratio of 0.78, p = 0.087 We matched 81 to 160 psoriatic arthritis patients, the median survival time on etanercept was 35.8. compared to 65.7 months, hazard ratio 1.61, p = 0.011. Patients treated with etanercept had significantly worse psoriasis scoring during follow up. CONCLUSIONS: We found comparable survival in rheumatoid arthritis and ankylosing spondylitis. In psoriatic arthritis, we found significantly shorter survival on etanercept, possibly due to worse response of skin and nail manifestations.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a etanercept $x terapeutické užití $7 D000068800
- 650 12
- $a revmatoidní artritida $x farmakoterapie $x mortalita $7 D001172
- 650 12
- $a ankylózující spondylitida $x farmakoterapie $x mortalita $7 D013167
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a psoriatická artritida $x farmakoterapie $x mortalita $7 D015535
- 650 12
- $a tendenční skóre $7 D057216
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a registrace $7 D012042
- 650 12
- $a antirevmatika $x terapeutické užití $7 D018501
- 650 12
- $a TNF-alfa $x antagonisté a inhibitory $7 D014409
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a monoklonální protilátky $x terapeutické užití $7 D000911
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a adalimumab $x terapeutické užití $7 D000068879
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a infliximab $x terapeutické užití $7 D000069285
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Nekvindová, L $u Institute of Biostatistics and Analyses Ltd., Brno, Czech Republic $1 https://orcid.org/0000000288662310 $7 xx0231716
- 700 1_
- $a Baranová, J $u Institute of Biostatistics and Analyses Ltd., Brno, Czech Republic
- 700 1_
- $a Vencovský, J $u Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000208510713 $7 jo20000080529
- 700 1_
- $a Pavelka, K $u Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000319528422 $7 jn99240000847
- 700 1_
- $a Horák, P $u Third Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc, Olomouc, Czech Republic $1 https://orcid.org/000000022394064X $7 xx0032850
- 700 1_
- $a Závada, J $u Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000298026545 $7 xx0160054
- 773 0_
- $w MED00010604 $t Scandinavian journal of rheumatology $x 1502-7732 $g Roč. 54, č. 2 (2025), s. 79-86
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39105330 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135052 $b ABA008
- 999 __
- $a ok $b bmc $g 2311260 $s 1246853
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 54 $c 2 $d 79-86 $e 20240806 $i 1502-7732 $m Scandinavian journal of rheumatology $n Scand J Rheumatol $x MED00010604
- LZP __
- $a Pubmed-20250415
